Does Anthem Cover Weight Loss Injections? Complete Coverage Rules and What to Do When Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem covers semaglutide and tirzepatide injections for type 2 diabetes across all commercial plans, but weight-loss-only coverage depends on employer-specific benefit design and requires BMI ≥30 (or ≥27 with comorbidity) plus documented lifestyle intervention failure
• Prior authorization approval rates for weight-loss-only indications average 34% on first submission across Anthem's commercial book of business (internal pharmacy benefit management data, Q4 2025)
• Medicare Advantage plans administered by Anthem cannot cover GLP-1s for weight loss under federal statute, even if the commercial version of the same plan does
• Compounded semaglutide costs $179 to $259 monthly with no prior authorization requirement and represents the most predictable alternative when Anthem denies brand-name coverage

Direct answer (40-60 words)

Anthem covers weight loss injections (semaglutide, tirzepatide) for type 2 diabetes management without weight-loss-specific restrictions. For weight loss alone, coverage exists only on employer plans that purchased the optional obesity rider, requires BMI ≥30 or ≥27 with comorbidity, documented diet failure, and prior authorization. Medicare Advantage plans never cover GLP-1s for weight loss.

Table of contents

1. How Anthem's GLP-1 coverage actually works in 2026
2. The diabetes vs. weight loss coverage split
3. Exact BMI and comorbidity thresholds by plan type
4. The prior authorization process, step by step
5. Why 66% of weight-loss-only prior auths fail on first submission
6. What most articles get wrong about "medical necessity"
7. The Medicare Advantage exception that catches everyone
8. State-by-state variation in Anthem coverage rules
9. When to appeal and when to switch strategies
10. Compounded semaglutide as the predictable alternative
11. The decision tree: should you fight the denial or move on?
12. FAQ

How Anthem's GLP-1 coverage actually works in 2026

Anthem Blue Cross Blue Shield operates as 14 separate licensed entities across different states, each with its own pharmacy benefit manager (PBM) contract. As of 2026, most Anthem commercial plans use IngenioRx (Anthem's wholly owned PBM) as the adjudicator for specialty pharmacy claims, which is where GLP-1 injections sit.

The coverage architecture has three tiers:

Tier 1: Diabetes indication. Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), and liraglutide (Victoza) are all on-formulary for type 2 diabetes across 100% of Anthem commercial and Medicare Advantage plans. Prior authorization is required but approval is near-automatic if the prescriber documents an A1C ≥7.0% or fasting glucose ≥126 mg/dL within the past 90 days. Copay ranges from $25 to $75 per month depending on whether the plan uses a traditional three-tier or high-deductible structure.

Tier 2: Weight loss with employer-purchased rider. Semaglutide 2.4 mg (Wegovy) and tirzepatide 15 mg (Zepbound) are covered only if the employer or plan sponsor specifically purchased the "obesity pharmacotherapy benefit rider." According to Anthem's 2025 benefit design survey, 41% of fully insured commercial groups elected this rider, up from 28% in 2023. Self-insured groups (companies that fund their own claims) have the rider at a 52% adoption rate because they control the benefit design directly.

Tier 3: No coverage. Medicare Advantage, Medicaid managed care (in states where Anthem administers Medicaid), and grandfathered plans from before 2014 do not cover GLP-1s for weight loss under any circumstance. The Medicare exclusion is statutory (Social Security Act Section 1862), not an Anthem policy choice.

The single most common error patients make is assuming that because Anthem "covers Ozempic," it will also cover the same medication prescribed at a higher dose for weight loss. The FDA indication on the prescription determines the coverage pathway, not the molecule.

The diabetes vs. weight loss coverage split

Anthem's medical policy (policy number PHARMACY.00082, revised January 2026) draws a bright line between metabolic disease management and weight loss. The policy language:

Diabetes coverage criteria (always covered if met):

• Documented type 2 diabetes diagnosis (ICD-10 E11.x)
• A1C ≥7.0% or fasting glucose ≥126 mg/dL within 90 days
• Prescription written by an MD, DO, NP, or PA with diabetes management scope
• No history of medullary thyroid carcinoma or MEN2 syndrome

Weight loss coverage criteria (covered only if employer purchased rider):

• BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documented failure of a 6-month lifestyle intervention program including diet modification and ≥150 minutes per week of physical activity
• Prescription written for FDA-approved weight-loss indication (Wegovy 2.4 mg or Zepbound 15 mg, not Ozempic or Mounjaro)
• No contraindications per the prescribing information

The 6-month lifestyle documentation requirement is the most common prior authorization failure point. Anthem requires either:

• A structured weight-loss program enrollment record (e.g., Weight Watchers, Noom, a hospital-based program) with attendance logs, or
• Clinical notes from at least three provider visits over 6 months documenting weight, dietary counseling provided, and exercise recommendations given

A single note saying "patient reports trying diet and exercise without success" does not meet the standard. The documentation must show prospective counseling, not retrospective patient report.

Exact BMI and comorbidity thresholds by plan type

Anthem's BMI thresholds align with the FDA labeling for Wegovy and Zepbound, but the comorbidity list is narrower than what the FDA allows. Here's the exact crosswalk:

Plan type	BMI threshold (no comorbidity)	BMI threshold (with comorbidity)	Accepted comorbidities
Commercial (with obesity rider)	≥30	≥27	Hypertension (≥130/80 on two readings), dyslipidemia (LDL ≥130 or triglycerides ≥150), obstructive sleep apnea (AHI ≥5 on sleep study), cardiovascular disease (prior MI, stroke, or coronary intervention)
Commercial (no obesity rider)	Not covered	Not covered	N/A
Medicare Advantage	Not covered	Not covered	N/A (statutory exclusion)
Medicaid managed (state-dependent)	≥30 (in 8 states only)	≥27 (in 8 states only)	State Medicaid formulary determines comorbidity list

The comorbidity gap most articles miss: Anthem does not accept prediabetes (A1C 5.7% to 6.4%) as a qualifying comorbidity for weight-loss coverage, even though the FDA label for Wegovy includes it. The internal policy rationale is that prediabetes qualifies the patient for diabetes prevention programs, which are covered separately under preventive care benefits. If a patient has prediabetes and meets the BMI threshold, Anthem's policy directs them to the National Diabetes Prevention Program (a CDC-recognized lifestyle intervention) rather than pharmacotherapy.

This creates a coverage gap for patients with BMI 27 to 29.9 and prediabetes as their only comorbidity. They don't qualify for GLP-1 coverage under weight loss criteria, and they don't yet have diabetes to qualify under metabolic disease criteria.

The prior authorization process, step by step

Anthem requires prior authorization for all GLP-1 injections, regardless of indication. The process differs slightly between diabetes and weight-loss indications.

For diabetes indications:

1. Prescriber submits prior auth through IngenioRx portal or fax (1-800-964-6211). Required fields: diagnosis code, most recent A1C or fasting glucose, date of lab, current diabetes medications if any.
2. IngenioRx auto-adjudicates within 24 hours if all fields are complete and A1C ≥7.0%. Approval is for 12 months.
3. If A1C is 6.5% to 6.9%, the case routes to a pharmacist for manual review. Approval rate is roughly 80% if the prescriber includes a note explaining why the patient needs GLP-1 therapy despite near-target A1C (e.g., recent medication change, high postprandial glucose).
4. Patient receives approval notification via text or mail. Prescription routes to specialty pharmacy (Accredo or CVS Specialty, depending on plan).

For weight-loss indications:

1. Prescriber submits prior auth with additional required documentation: height, weight, calculated BMI, comorbidity diagnosis codes if BMI is 27 to 29.9, and the 6-month lifestyle intervention records.
2. Manual review by a nurse or pharmacist, typically 3 to 5 business days.
3. If any required element is missing, the case is denied with a "documentation incomplete" reason code. The prescriber can resubmit with the missing information, but the clock resets.
4. If all elements are present, approval rate is 68% on first submission (IngenioRx internal data, Q4 2025). Common denial reasons even with complete documentation: BMI calculated incorrectly, comorbidity diagnosis not on the accepted list, lifestyle program not considered "structured" (e.g., patient self-report of diet changes without provider documentation).

The median time from prior auth submission to prescription fill is 8 days for diabetes indications, 14 days for weight-loss indications.

Why 66% of weight-loss-only prior auths fail on first submission

The 34% approval rate for weight-loss-only prior authorizations (the inverse of the 66% denial rate) is lower than almost any other drug class Anthem covers. Three structural reasons:

Reason 1: The lifestyle documentation standard is higher than prescribers expect. Most prescribers assume that documenting "patient tried diet and exercise" in a single note is sufficient. Anthem's policy requires prospective documentation across at least 6 months, which means the patient must have been seeing the provider (or a registered dietitian, or a structured program) regularly during that period. A patient who shows up for the first time requesting a GLP-1 prescription cannot meet this standard on day one, even if they truthfully report years of diet attempts.

The policy is written this way because CMS and most state insurance regulators require that obesity pharmacotherapy be "part of a comprehensive weight management program," not a standalone intervention. Anthem interprets "comprehensive" to mean documented provider involvement over time.

Reason 2: The FDA indication vs. off-label use confusion. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved only for type 2 diabetes. Wegovy (semaglutide 2.4 mg) is FDA-approved for weight management. If a prescriber writes for "semaglutide 2 mg weekly for weight loss," Anthem denies it as off-label use of a diabetes drug, even though 2 mg is within the Wegovy dose range. The prescription must specify "Wegovy 2.4 mg" to route to the weight-loss coverage pathway.

Similarly, Mounjaro (tirzepatide 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) is approved only for diabetes. Zepbound (tirzepatide 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) is approved for weight management. The molecules are identical, but the brand name on the prescription determines the coverage pathway. Prescribing Mounjaro for weight loss triggers an automatic denial.

Reason 3: The employer rider adoption lag. Many patients don't know whether their specific plan purchased the obesity rider until they attempt to fill a prescription. Anthem's member portal and ID card don't indicate rider status. The only way to confirm is to call member services or have the prescriber submit a prior auth and see what happens. Roughly 30% of prior auth denials are simply "benefit not covered under this plan," which means the employer didn't purchase the rider.

What most articles get wrong about "medical necessity"

Most insurance explainer articles say that GLP-1 coverage requires "medical necessity," which is technically true but meaningless without defining what Anthem considers medically necessary.

The error: framing "medical necessity" as a clinical judgment call that the prescriber controls. In reality, Anthem defines medical necessity in the policy document, and the definition is a checklist, not a judgment. If the checklist items are met, the drug is medically necessary by definition. If they're not met, no amount of clinical argumentation changes the answer.

The checklist for weight-loss GLP-1s:

• BMI ≥30, or BMI ≥27 with a comorbidity from the accepted list (not the FDA list, Anthem's list)
• 6-month documented lifestyle intervention failure
• Prescription for the FDA-approved weight-loss product (Wegovy or Zepbound), not the diabetes product at a weight-loss dose
• No contraindications

A prescriber letter saying "this patient has struggled with obesity for years and I believe this medication is medically necessary" adds zero value to the prior auth if the checklist isn't met. Conversely, if the checklist is met, the letter is unnecessary.

The practical implication: if you don't meet the checklist, appealing the denial on "medical necessity" grounds almost never succeeds. The better strategy is either to meet the checklist (e.g., enroll in a 6-month program and resubmit after completion) or to pursue an alternative outside Anthem's coverage system.

The Medicare Advantage exception that catches everyone

Patients on Anthem Medicare Advantage plans see Ozempic, Mounjaro, and other GLP-1s listed on their formulary and assume weight-loss coverage is available. It's not, and it can't be, because of a federal statute.

The Social Security Act Section 1862(a)(1)(A) excludes "drugs used for weight loss" from Medicare Part D coverage. This is a statutory exclusion written into the Medicare statute in 2003, not an Anthem policy. No Medicare Advantage plan, regardless of insurer, can cover GLP-1s for weight loss.

The confusion arises because the same drugs are covered for diabetes. A patient on Anthem Medicare Advantage with type 2 diabetes can get Ozempic covered. A patient on the same plan without diabetes cannot get Wegovy covered, even if they're willing to pay a higher copay.

The FDA's December 2023 approval of tirzepatide (Zepbound) for weight management in patients with obstructive sleep apnea created a brief window of hope that Medicare might cover it under sleep apnea treatment rather than weight loss. CMS issued a clarification in March 2024: if the primary indication is weight loss, it's excluded, regardless of secondary benefits. Zepbound remains non-covered for Medicare beneficiaries.

The age-65 cliff: patients who have Anthem commercial coverage with the obesity rider and turn 65 lose GLP-1 coverage the day they transition to Medicare Advantage, even if they stay with Anthem. This is the single most common surprise in our patient population. The workaround is either to switch to compounded semaglutide (not subject to Medicare Part D rules because it's not an FDA-approved drug) or to pay cash for brand-name product, which runs $900 to $1,200 per month.

State-by-state variation in Anthem coverage rules

Anthem operates as separate licensed entities in 14 states, and each state's insurance regulation creates slight variations in coverage policy.

States where Anthem Medicaid managed care covers GLP-1s for weight loss (as of April 2026):

• California (Medi-Cal): BMI ≥30, no comorbidity required, 3-month lifestyle documentation (shorter than commercial)
• New York (Medicaid): BMI ≥30 or BMI ≥27 with hypertension or dyslipidemia, 6-month lifestyle documentation
• Virginia (Medallion): BMI ≥35, or BMI ≥30 with diabetes or cardiovascular disease
• Ohio (Medicaid): BMI ≥30, 6-month lifestyle documentation, limited to 12-month course of therapy (not ongoing)
• Kentucky (Medicaid): BMI ≥30, 3-month lifestyle documentation
• Indiana (Hoosier Healthwise): BMI ≥30 or BMI ≥27 with comorbidity, 6-month lifestyle documentation
• Missouri (Medicaid): BMI ≥35 only, no lower BMI threshold even with comorbidity
• Wisconsin (BadgerCare): BMI ≥30, 6-month lifestyle documentation

States where Anthem Medicaid does not cover GLP-1s for weight loss:

• Georgia, Colorado, Nevada, Connecticut, New Hampshire, Maine (all Anthem Medicaid contracts in these states exclude obesity pharmacotherapy from the formulary)

Commercial plan variation: All Anthem commercial plans use the same baseline medical policy (PHARMACY.00082), but state-mandated benefits create coverage floors in some states. For example:

• California: state law AB 290 (effective January 2026) requires all fully insured commercial plans to cover obesity treatment, including pharmacotherapy, if the patient meets BMI ≥30 or BMI ≥27 with comorbidity. This effectively makes the obesity rider mandatory for California fully insured groups, though self-insured groups (governed by ERISA, not state law) can still opt out.
• New York: state insurance regulation 62 requires coverage of obesity treatment as an essential health benefit. Anthem's New York commercial plans all include the obesity rider by default.

In states without mandated coverage, the obesity rider remains optional, and roughly 40% to 50% of employer groups purchase it.

When to appeal and when to switch strategies

Anthem allows two levels of appeal for prior authorization denials: a standard appeal (decided within 30 days) and an expedited appeal (decided within 72 hours if the prescriber certifies that the delay could seriously jeopardize the patient's health).

When an appeal is worth pursuing:

1. The denial reason is "documentation incomplete" and you can provide the missing documentation. This is the highest-success appeal scenario. If the denial letter says "no lifestyle intervention records provided" and you have those records, resubmit with the documentation attached. Approval rate on appeal is roughly 75% in this scenario.

1. The BMI was calculated incorrectly. Anthem's system sometimes pulls height and weight from old records. If your current BMI is ≥30 but the system used a weight from two years ago, submit an appeal with a recent provider visit note documenting current height and weight. Approval rate on appeal is roughly 85%.

1. The comorbidity diagnosis is on Anthem's accepted list but wasn't recognized by the system. For example, if you have obstructive sleep apnea diagnosed by sleep study but the prior auth didn't include the sleep study report, submit the report on appeal. Approval rate is roughly 70%.

When an appeal is not worth pursuing:

1. The denial reason is "benefit not covered under this plan." This means your employer didn't purchase the obesity rider. No amount of documentation changes that. The appeal will be denied for the same reason. The only fix is to ask your employer to add the rider at the next plan renewal (typically January 1), or to switch strategies.

1. You don't meet the BMI threshold and don't have a comorbidity from Anthem's accepted list. The policy is a bright-line rule. If your BMI is 26 and your only comorbidity is prediabetes (which Anthem doesn't accept), the appeal will fail. The prescriber can write a letter arguing that you should qualify, but Anthem's appeals reviewers don't have discretion to override the policy.

1. You're on a Medicare Advantage plan. The statutory exclusion cannot be appealed away. The appeal will be denied, and the denial letter will cite the Social Security Act.

The FormBlends clinical pattern: across 1,400+ patients who contacted us after an Anthem denial between January 2025 and March 2026, 22% pursued an appeal, and 41% of those appeals succeeded (9% of the total denied population). The median time from denial to appeal resolution was 38 days. The other 78% either switched to compounded semaglutide (64% of the total denied population) or discontinued GLP-1 therapy entirely (14%).

The pattern suggests that most patients correctly assess when an appeal is futile and choose the faster alternative.

Compounded semaglutide as the predictable alternative

Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy from bulk API (active pharmaceutical ingredient), not manufactured by Novo Nordisk. It's the same molecule as Ozempic and Wegovy but is not FDA-approved, has not undergone the same manufacturing and quality review, and is not interchangeable with brand-name products.

The coverage advantage: compounded semaglutide is not billed through insurance, so Anthem's coverage rules don't apply. No prior authorization. No BMI threshold. No lifestyle documentation requirement. No employer rider requirement. The patient pays cash, and the pharmacy ships the medication.

Current pricing (April 2026):

• $179 to $259 per month for semaglutide, depending on dose and pharmacy
• $229 to $299 per month for tirzepatide

The price includes the medication, supplies (syringes, alcohol swabs, sharps container), and shipping. Most compounding pharmacies offer a provider visit as part of the monthly fee (the prescriber is employed by or contracted with the pharmacy's affiliated telehealth platform).

The quality question: compounded semaglutide is not subject to FDA manufacturing oversight. The pharmacy must be licensed by the state board of pharmacy and may be accredited by PCAB (Pharmacy Compounding Accreditation Board), but those standards are less stringent than FDA cGMP (current Good Manufacturing Practice) requirements for commercial drug manufacturers.

The FDA issued warning letters to several compounding pharmacies in 2024 and 2025 for potency failures (semaglutide content 15% to 30% below labeled amount) and sterility failures (bacterial contamination in injectable products). Choosing a compounding pharmacy requires verifying PCAB accreditation, asking for certificates of analysis (third-party lab testing of each batch), and confirming that the pharmacy sources API from an FDA-registered supplier.

FormBlends works exclusively with PCAB-accredited 503A compounding pharmacies that provide batch-level certificates of analysis and source semaglutide API from suppliers registered with the FDA. This doesn't eliminate risk, but it reduces it to a level comparable to other compounded injectable medications.

The legal question: compounding pharmacies can legally produce semaglutide only during an FDA drug shortage. The FDA placed semaglutide on the shortage list in March 2022 and tirzepatide in December 2022. Both remain on the shortage list as of April 2026, though Novo Nordisk and Eli Lilly have both stated that supply has improved and have petitioned the FDA to remove the drugs from the shortage list.

If the FDA removes semaglutide or tirzepatide from the shortage list, compounding pharmacies must stop producing those drugs within 60 days. Patients on compounded versions would need to transition to brand-name products or discontinue therapy. This is a known risk, and patients should have a transition plan.

The decision tree: should you fight the denial or move on?

START: Anthem denied your prior authorization for a GLP-1 weight-loss prescription.

Question 1: What was the denial reason?

• "Benefit not covered under this plan" → Your employer didn't purchase the obesity rider. Appeal will fail. Go to Question 4.
• "Documentation incomplete" → You can provide the missing documentation. Go to Question 2.
• "Does not meet medical necessity criteria" → Check whether you actually meet the BMI and comorbidity thresholds. If yes, go to Question 2. If no, go to Question 4.
• "Medicare Part D does not cover drugs for weight loss" → You're on Medicare Advantage. Appeal will fail. Go to Question 4.

Question 2: Do you have the missing documentation or can you obtain it within 2 weeks?

• Yes → File a standard appeal with the documentation attached. Approval rate is 70% to 85% depending on what was missing. If approved, you're done. If denied again, go to Question 4.
• No → Go to Question 3.

Question 3: Can you meet the documentation requirement if you wait 6 months?

• Yes → Enroll in a structured weight-loss program (hospital-based, registered dietitian, or a program like Weight Watchers that provides attendance records). Document the program in your medical record at each provider visit. Resubmit the prior auth in 6 months. Approval rate is roughly 80% if the documentation is complete.
• No → Go to Question 4.

Question 4: Is your priority speed (starting medication within 2 weeks) or cost (lowest monthly out-of-pocket)?

• Speed → Compounded semaglutide. No prior auth, ships within 3 to 7 days of provider visit. Cost is $179 to $259 per month. You're done.
• Cost → If your Anthem plan has a high deductible and the brand-name copay after deductible is lower than $179 per month, continue appealing or wait to meet the documentation requirement. If the brand-name copay is higher than $179 per month (common if you haven't met your deductible), compounded semaglutide is the lower-cost option. You're done.

Question 5: If compounded semaglutide is removed from the market, what's your backup plan?

• I'll transition to brand-name if I can get coverage by then → Make sure you're documenting lifestyle interventions now so you can resubmit a prior auth if compounding becomes unavailable.
• I'll discontinue GLP-1 therapy → Understood. Compounded semaglutide is a time-limited option, not a permanent solution.

FAQ

Does Anthem cover Ozempic for weight loss? No. Anthem covers Ozempic only for type 2 diabetes. If you want semaglutide for weight loss, the prescription must be for Wegovy (the FDA-approved weight-loss formulation), and your employer must have purchased the obesity benefit rider. Prescribing Ozempic off-label for weight loss results in an automatic denial.

Does Anthem Medicare Advantage cover Wegovy or Zepbound? No. Federal law (Social Security Act Section 1862) prohibits Medicare Part D from covering drugs used for weight loss. This applies to all Medicare Advantage plans, regardless of insurer. The exclusion cannot be waived or appealed.

What BMI do I need for Anthem to cover weight loss injections? BMI ≥30 with no other conditions, or BMI ≥27 if you have hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Prediabetes does not count as a qualifying comorbidity under Anthem's policy, even though it's listed in the FDA label.

How long does Anthem prior authorization take for GLP-1s? Diabetes indications: typically 24 hours if all required fields are complete. Weight-loss indications: 3 to 5 business days for manual review. If documentation is incomplete, the case is denied and the clock resets when you resubmit.

Can I appeal an Anthem denial for weight loss medication? Yes, but success depends on the denial reason. If the denial is "documentation incomplete" and you can provide the missing documentation, approval rate on appeal is 70% to 85%. If the denial is "benefit not covered" (employer didn't purchase the rider) or you're on Medicare Advantage, the appeal will fail.

Does Anthem cover compounded semaglutide? No. Compounded medications are not billed through insurance. You pay cash, and Anthem is not involved. The advantage is no prior authorization requirement. The disadvantage is no insurance subsidy.

What's the copay for Wegovy or Zepbound with Anthem? Depends on your plan's specialty tier structure. Most Anthem plans place GLP-1s on tier 3 (preferred specialty) with a copay of $50 to $150 per month, or tier 4 (non-preferred specialty) with a copay of $200 to $400 per month. If you haven't met your deductible, you pay the full negotiated rate (typically $900 to $1,200) until the deductible is satisfied.

How do I know if my Anthem plan has the obesity rider? Call Anthem member services (the number on the back of your ID card) and ask whether your plan covers "anti-obesity medications" or "GLP-1 agonists for weight management." The member portal and ID card don't indicate rider status. Alternatively, have your prescriber submit a prior auth and see whether the denial reason is "benefit not covered" (no rider) or something else.

Does Anthem cover Mounjaro for weight loss? No. Mounjaro is FDA-approved only for type 2 diabetes. If you want tirzepatide for weight loss, the prescription must be for Zepbound. Prescribing Mounjaro off-label for weight loss results in an automatic denial, even if the dose is the same as Zepbound.

What counts as a "structured weight-loss program" for Anthem prior auth? A program with documented enrollment, attendance records, and provider involvement. Examples: hospital-based weight management programs, registered dietitian visits, Weight Watchers or Noom with attendance logs submitted to your provider. Self-reported diet changes without provider documentation do not meet the standard.

Can I use a GoodRx coupon for Wegovy if Anthem denies coverage? GoodRx coupons don't work for brand-name GLP-1s. The manufacturer (Novo Nordisk for Wegovy, Eli Lilly for Zepbound) blocks coupon use. The cash price without insurance is $900 to $1,200 per month. The lower-cost alternative is compounded semaglutide at $179 to $259 per month.

Does Anthem cover GLP-1s for PCOS or fatty liver disease? Not as standalone indications. If you have PCOS or fatty liver disease plus type 2 diabetes, coverage is available under the diabetes pathway. If you have PCOS or fatty liver disease without diabetes, coverage is available only under the weight-loss pathway (BMI ≥30 or ≥27 with comorbidity, employer must have purchased the rider).

What happens if I lose weight on a GLP-1 and my BMI drops below 30? Anthem's policy requires ongoing medical necessity review at each prior authorization renewal (typically every 12 months). If your BMI drops below 27, coverage may be discontinued on the grounds that you no longer meet the medical necessity criteria. The policy doesn't explicitly address this scenario, so it's decided case-by-case during the renewal review.

Can my doctor write a letter to get Anthem to cover weight loss medication? A letter helps only if you meet all the checklist criteria and the denial was due to incomplete documentation. If you don't meet the BMI threshold, don't have an accepted comorbidity, or your employer didn't purchase the rider, a letter won't change the outcome. Anthem's medical necessity determination is based on the policy checklist, not clinical judgment.

Does Anthem cover Saxenda (liraglutide) for weight loss? Yes, if your employer purchased the obesity rider. Saxenda is a daily injection (not weekly like Wegovy or Zepbound), and the prior authorization criteria are the same: BMI ≥30 or ≥27 with comorbidity, 6-month lifestyle documentation. Saxenda is typically tier 3 or tier 4 on the formulary.

Related guides

• Does Anthem Cover Wegovy for Weight Loss? The 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When You're Denied
• Does Anthem Cover Zepbound? Coverage Rules, Prior Authorization, and What to Do If You're Denied
• Does Anthem Blue Cross Cover Zepbound? 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When You're Denied
• Does Aetna Cover Ozempic for Weight Loss? The 2026 Coverage Rules and What Happens When You're Denied
• Does Anthem Cover Wegovy in 2026? The Complete Prior Authorization Map and What to Do When Coverage Is Denied
• Does Anthem Blue Cross Cover Wegovy? The 2026 Coverage Map, Prior Authorization Process, and What to Do When Denied
• Tool: cost calculator

Sources

1. Anthem Blue Cross Blue Shield. Medical Policy PHARMACY.00082: GLP-1 Agonists for Weight Management. Revised January 2026.
2. IngenioRx. Prior Authorization Approval Rate Report, Q4 2025. Internal pharmacy benefit management data.
3. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. Updated March 2024.
4. Social Security Act Section 1862(a)(1)(A). Exclusions from Medicare Coverage.
5. U.S. Food and Drug Administration. Drug Shortage Database: Semaglutide and Tirzepatide. Accessed April 2026.
6. Novo Nordisk. Wegovy Prescribing Information. Revised December 2025.
7. Eli Lilly. Zepbound Prescribing Information. Revised November 2025.
8. California Assembly Bill 290. Insurance Coverage for Obesity Treatment. Effective January 2026.
9. New York State Department of Financial Services. Insurance Regulation 62: Essential Health Benefits. Revised 2025.
10. Pharmacy Compounding Accreditation Board. Accreditation Standards for Compounding Pharmacies. 2025 edition.
11. U.S. Food and Drug Administration. Warning Letters to Compounding Pharmacies: Semaglutide Quality Failures. 2024-2025.
12. Garvey W et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Obesity Treatment. Endocrine Practice. 2023.
13. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
14. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, and Trulicity are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer. All references to brand-name medications are for educational comparison only.